The VIPR2 antibody targets the vasoactive intestinal peptide receptor 2 (VIPR2), a class B G protein-coupled receptor (GPCR) that binds vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). VIPR2 is widely expressed in tissues, including the brain, immune cells, and endocrine organs, where it regulates diverse physiological processes such as circadian rhythms, immune modulation, and hormonal secretion. It activates intracellular signaling pathways (e.g., cAMP/PKA, MAPK) upon ligand binding, influencing cellular proliferation, differentiation, and inflammation.
VIPR2 antibodies are essential tools for studying receptor localization, expression levels, and function in both normal and pathological contexts. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore VIPR2's role in diseases such as neurodegenerative disorders, autoimmune conditions, and cancer. For instance, altered VIPR2 signaling has been implicated in disrupted circadian rhythms (e.g., in schizophrenia) and chronic inflammatory diseases. Researchers also utilize these antibodies to evaluate therapeutic strategies targeting VIPR2. including drug development and biomarker discovery. Challenges in antibody development include ensuring specificity due to structural similarities among class B GPCRs. Recent studies highlight VIPR2's potential as a therapeutic target, driving demand for high-affinity, validated antibodies.